Clinical-stage USA-based drug developer Inhibikase Therapeutics (Nasdaq: IKT) saw its shares tumble more than 31% to $1.92, after is revealed that it is pausing development of risvodetinib following disappointing results from a Phase II trial of patients with untreated Parkinson's disease.
The 201 Trial enrolled 126 people with untreated Parkinson’s disease who were, on average, 14 months from diagnosis and were dosed in equal proportions at 50mg, 100mg, 200mg or placebo for 12 weeks. The primary endpoints of this trial were safety and tolerability and there were 15 secondary endpoints to evaluate treatment benefit.
While the drug was generally well tolerated, with adverse events comparable to placebo, it failed to demonstrate significant improvement in combined motor scores on the Movement Disorder Society Universal Parkinson’s Disease Rating Scale (MDS-UPDRS).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze